Immuno Cure BioTech is pleased to announce today the initiation of a Phase I clinical study of ICVAX, a therapeutic DNA vaccine for HIV, in collaboration with the Faculty of Medicine of The Chinese University of Hong Kong (“CU Medicine”), the AIDS Institute of The University of Hong Kong (“HKU AIDS Institute”), and Greater Bay Area International Clinical Trials Center (“BAY TRIAL”).
Yicura Debuts Encouraging ICVAX IIT Results at BIO 2026
Learn MoreTender Result Announcement for Contract Research Organization Services of Phase II Clinical Trial of Therapeutic DNA Injections for HIV/AIDS (ICVAX)
Learn MoreImmuno Cure Deploys Scientist Team to Manage Research Facility for Therapeutic DNA Vaccine for HIV at Center of International Innovation for Technology and Science
Learn MoreImmuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong
Tender for Contract Research Organization Services of Phase II Clinical Trial of Therapeutic DNA Injections for HIV/AIDS (ICVAX)
Interested tenderers shall request an electronic copy of the tender document by emailing Mr. Carl Cheng at (carlcheng@immunocure.hk). The request must include the company name, email, and the contact details of the correspondence person.
Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition
“a prominent recognition attracting RMB 60M investment EOI”
